Bayer AG and J&J’s subsidiary Janssen Pharmaceuticals Inc. have now formalized a $775 settlement of more than 25,000 lawsuits over their blood-thinning drug Xarelto. The cases are pending in both federal and state courts and this may be seen as a run up to Bayer’s next settlement, in their now seen as a bad-for-earnings purchase of Monsanto and its Federal Roundup MDL 2471 docket, as well as cases filed in state courts.
Xarelto Litigation Settles for $775 million Bayer and Johnson & Johnson Split Bill
